Previous 10 | Next 10 |
Two-year Results from ARTISAN-SNM Study to be Presented at Plenary Session Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatmen...
Axonics Modulation Technologies (AXNX) receives PMA supplement approval from the FDA for its third-generation implantable neurostimulator ((INS)). The third-generation INS upgrades the embedded software in the INS and the functionality of the patient remote control. Shipment of the third-gene...
Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, has received PMA supplement approval from the U.S. Food...
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, will participate in the virtual SVB Leerink Global Heal...
For Q4, Axonics Modulation Technologies (AXNX) expects net revenue to be in the range of $34.7-$34.9M vs. $9.9M reported in the year ago quarter.U.S. customers sales represented ~97% of total revenue.In Q4, ~320 confirmed and scheduled permanent implants were canceled due to COVID-19 bas...
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today reported preliminary unaudited net revenue for th...
Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced the appointment of veteran medical tech...
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, is scheduled to participate in the Piper Sandler Virtua...
Patients experienced significant clinical benefits and satisfaction with recharging and therapy Clinical outcomes consistent with dual incontinence patients from ARSTISAN pivotal study Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology...
Axonics Modulation Technologies, Inc. (AXNX) Q3 2020 Earnings Conference Call November 4, 2020 4:30 PM ET Company Participants Neil Bhalodkar - Investor Relations Raymond Cohen - Chief Executive Officer Dan Dearen - President and Chief Financial Officer Conference Call Participants David Lewi...
News, Short Squeeze, Breakout and More Instantly...
Axonics Modulation Technologies Inc. Company Name:
AXNX Stock Symbol:
NASDAQ Market:
Axonics Modulation Technologies Inc. Website:
Axonics, Inc. (NASDAQ: AXNX) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 0.09% on the day to $68.5. Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulat...
Generated record revenue, gross margin and net income in 2Q24 Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops, manufactures and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results f...
Viridien ADR (CGGYD) is expected to report for Q2 2024 Civitas Resources Inc. (CIVI) is expected to report $2.9 for Q2 2024 Aptiv PLC (APTV) is expected to report $1.37 for Q2 2024 Ardelyx Inc. (ARDX) is expected to report $-0.1 for Q2 2024 Beazer Homes USA Inc. (BZH) is expected ...